CD274 and non-small cell lung carcinoma: In the first-line setting of advanced NSCLC patients without driver alterations that can be targeted, nivolumab plus ipilimumab dwarfed chemotherapy with an additional 1.83 LYs, 0.71 Lys, and 1.37 LYs in the PD-L1 expression ≥50, ≥1, and <1% populations, respectively.